225 related articles for article (PubMed ID: 26251183)
21. Family-based whole-exome sequencing identifies rare variants potentially related to cutaneous melanoma predisposition in Brazilian melanoma-prone families.
Fidalgo F; Torrezan GT; Sá BCS; Barros BDF; Moredo LF; Valieris R; de Souza SJ; Duprat JP; Krepischi ACV; Carraro DM
PLoS One; 2022; 17(1):e0262419. PubMed ID: 35085295
[TBL] [Abstract][Full Text] [Related]
22. Constitutional variants in POT1, TERF2IP, and ACD genes in patients with melanoma in the Polish population.
Malińska K; Deptuła J; Rogoża-Janiszewska E; Górski B; Scott R; Rudnicka H; Kashyap A; Domagała P; Hybiak J; Masojć B; Cybulski C; Kram A; Boer M; Kiedrowicz M; Lubiński J; Dębniak T
Eur J Cancer Prev; 2020 Nov; 29(6):511-519. PubMed ID: 32976206
[TBL] [Abstract][Full Text] [Related]
23. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
Bellido F; Pineda M; Aiza G; Valdés-Mas R; Navarro M; Puente DA; Pons T; González S; Iglesias S; Darder E; Piñol V; Soto JL; Valencia A; Blanco I; Urioste M; Brunet J; Lázaro C; Capellá G; Puente XS; Valle L
Genet Med; 2016 Apr; 18(4):325-32. PubMed ID: 26133394
[TBL] [Abstract][Full Text] [Related]
24. A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers.
Wilson TL; Hattangady N; Lerario AM; Williams C; Koeppe E; Quinonez S; Osborne J; Cha KB; Else T
Fam Cancer; 2017 Oct; 16(4):561-566. PubMed ID: 28389767
[TBL] [Abstract][Full Text] [Related]
25. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
26. Multiplex melanoma families are enriched for polygenic risk.
Law MH; Aoude LG; Duffy DL; Long GV; Johansson PA; Pritchard AL; Khosrotehrani K; Mann GJ; Montgomery GW; Iles MM; Cust AE; Palmer JM; ; Shannon KF; Spillane AJ; Stretch JR; Thompson JF; Saw RPM; Scolyer RA; Martin NG; Hayward NK; MacGregor S
Hum Mol Genet; 2020 Oct; 29(17):2976-2985. PubMed ID: 32716505
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
28. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
[TBL] [Abstract][Full Text] [Related]
29. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
30. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
[TBL] [Abstract][Full Text] [Related]
31. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
[TBL] [Abstract][Full Text] [Related]
32. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures.
Castellsagué E; Li R; Aligue R; González S; Sanz J; Martin E; Velasco À; Capellá G; Stewart CJR; Vidal A; Majewski J; Rivera B; Polak P; Matias-Guiu X; Brunet J; Foulkes WD
Hum Mutat; 2019 Jan; 40(1):36-41. PubMed ID: 30362666
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
[TBL] [Abstract][Full Text] [Related]
34. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer.
Elsayed FA; Kets CM; Ruano D; van den Akker B; Mensenkamp AR; Schrumpf M; Nielsen M; Wijnen JT; Tops CM; Ligtenberg MJ; Vasen HF; Hes FJ; Morreau H; van Wezel T
Eur J Hum Genet; 2015 Aug; 23(8):1080-4. PubMed ID: 25370038
[TBL] [Abstract][Full Text] [Related]
35. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
[TBL] [Abstract][Full Text] [Related]
36. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
37. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.
Berg P; Wennberg AM; Tuominen R; Sander B; Rozell BL; Platz A; Hansson J
Melanoma Res; 2004 Aug; 14(4):251-5. PubMed ID: 15305154
[TBL] [Abstract][Full Text] [Related]
38. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
39. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract][Full Text] [Related]
40. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
